Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Arroyo

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
Frontiers in Immunology|October 16, 2023
Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: <i>in vivo</i> antiviral activity and clinical responseMaría Inmaculada Domínguez-Mozo, Inés González-Suárez, Luisa María Villar, et al.
Plos One|May 3, 2013
Fine mapping and functional analysis of the multiple sclerosis risk gene CD6Bhairavi Swaminathan, Angélica Cuapio, Iraide Alloza, et al.
Plos One|July 17, 2010
CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibilityFiona Blanco-Kelly, Fuencisla Matesanz, Antonio Alcina, et al.
Peerj|November 26, 2020
Acetate correlates with disability and immune response in multiple sclerosisSilvia Pérez-Pérez, María Inmaculada Domínguez-Mozo, Aitana Alonso-Gómez, et al.
Heart Rhythm|May 19, 2024
2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to playRachel Lampert, Eugene H Chung, Michael J Ackerman, et al.
Scientific Reports|August 30, 2020
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumabMaria Inmaculada Dominguez-Mozo, Silvia Perez-Perez, Luisa María Villar, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2015
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.
Clinical Immunology (Orlando, Fla.)|June 5, 2017
Multimarker risk stratification approach at multiple sclerosis onsetLidia Fernández-Paredes, Armanda Casrouge, Jérémie Decalf, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2014
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II allelesBelén de la Hera, Elena Urcelay, David Brassat, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
Frontiers in Immunology|October 16, 2023
Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: <i>in vivo</i> antiviral activity and clinical responseMaría Inmaculada Domínguez-Mozo, Inés González-Suárez, Luisa María Villar, et al.
Plos One|May 3, 2013
Fine mapping and functional analysis of the multiple sclerosis risk gene CD6Bhairavi Swaminathan, Angélica Cuapio, Iraide Alloza, et al.
Plos One|July 17, 2010
CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibilityFiona Blanco-Kelly, Fuencisla Matesanz, Antonio Alcina, et al.
Peerj|November 26, 2020
Acetate correlates with disability and immune response in multiple sclerosisSilvia Pérez-Pérez, María Inmaculada Domínguez-Mozo, Aitana Alonso-Gómez, et al.
Heart Rhythm|May 19, 2024
2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to playRachel Lampert, Eugene H Chung, Michael J Ackerman, et al.
Scientific Reports|August 30, 2020
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumabMaria Inmaculada Dominguez-Mozo, Silvia Perez-Perez, Luisa María Villar, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2015
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.
Clinical Immunology (Orlando, Fla.)|June 5, 2017
Multimarker risk stratification approach at multiple sclerosis onsetLidia Fernández-Paredes, Armanda Casrouge, Jérémie Decalf, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2014
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II allelesBelén de la Hera, Elena Urcelay, David Brassat, et al.
Pageof 12